Fig. 4: Clinical outcomes of pyrotinib therapy in HER2 amplification-negative patients harbouring HER2 mutations. | npj Breast Cancer

Fig. 4: Clinical outcomes of pyrotinib therapy in HER2 amplification-negative patients harbouring HER2 mutations.

From: Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer

Fig. 4

a Maximum reduction in target lesions from baseline for HER2 amplification-negative, mutation-positive patients treated with pyrotinib. b Distribution of HER2 mutations in ten patients treated with pyrotinib. The symbols ⬦, *, # and ☆ represent concurrent HER2 mutations in the same patient. c PFS of pyrotinib-treated HER2 amplification-negative, mutation-positive patients stratified according to the PIK3CA mutation status.

Back to article page